Gastroenterology
Volume 138, Issue 1 , Pages 266-274, January 2010

The β3-Adrenoceptor Agonist GW427353 (Solabegron) Decreases Excitability of Human Enteric Neurons via Release of Somatostatin

  • Michael Schemann

      Affiliations

    • Human Biology, Technische Universität München, Freising, Germany
    • Corresponding Author InformationReprint requests Address requests for reprints to: Prof. Michael Schemann, Human Biology, Technische Universität München, Liesel-Beckmann-Strasse, D-85350 Freising-Weihenstephan, Germany. fax: (49) 8161 71 5785
  • ,
  • Nadia Hafsi

      Affiliations

    • Human Biology, Technische Universität München, Freising, Germany
  • ,
  • Klaus Michel

      Affiliations

    • Human Biology, Technische Universität München, Freising, Germany
  • ,
  • Olivia I. Kober

      Affiliations

    • Immuno Inflammation Centre of Excellence in Drug Discovery, GlaxoSmithKline, Middlesex, United Kingdom
    • Faculty of Medical and Veterinary Sciences, Cellular and Molecular Medicine Department, University of Bristol, Bristol, United Kingdom
  • ,
  • Jutta Wollmann

      Affiliations

    • Human Biology, Technische Universität München, Freising, Germany
  • ,
  • Qin Li

      Affiliations

    • Human Biology, Technische Universität München, Freising, Germany
  • ,
  • Florian Zeller

      Affiliations

    • Surgery, Clinic Freising, Freising, Germany
  • ,
  • Rupert Langer

      Affiliations

    • Department of Pathology, Technische Universität München, München, Germany
  • ,
  • Kevin Lee

      Affiliations

    • Immuno Inflammation Centre of Excellence in Drug Discovery, GlaxoSmithKline, Middlesex, United Kingdom
  • ,
  • Selim Cellek

      Affiliations

    • Immuno Inflammation Centre of Excellence in Drug Discovery, GlaxoSmithKline, Middlesex, United Kingdom

Received 12 January 2009; accepted 17 September 2009. published online 27 September 2009.

Background & Aims

β3 Adrenoceptor (β3-AR) is expressed on adipocytes and enteric neurons. GW427353 is a human selective β3-AR agonist with visceral analgesic effects. Some of its effects may involve release of somatostatin (SST) and actions on enteric neurons. The aim of this study was to investigate the mode of action of GW427353 in human submucous neurons.

Methods

Voltage sensitive dye imaging was used to record from human submucous neurons. SST release from human primary adipocytes was measured with enzyme-linked immunoabsorbent assay. Immunohistochemistry was used to detect adiponectin, β3-AR, SST, SST2 receptors, tyrosine hydroxylase (TH), and protein gene product 9.5.

Results

Confocal imaging showed cytoplasmic β3-AR labeling in somata of submucous neurons and nerve varicosities. GW427353 had no direct postsynaptic actions but decreased fast synaptic input to submucous neurons. Tissue perfusion with GW427353 reduced nicotine-evoked neuronal spike frequency, an effect prevented by the β3-AR antagonist SR-59230 and the SST2-receptor antagonist CYN154806 and mimicked by the SST2 receptor agonist octreotide. Adipocytes expressed adiponectin, β3-AR, and SST. TH-positive fibers were in close proximity to adipocytes. Submucous neurons expressed SST2 receptors. Human primary adipocytes released SST in response to GW427353 in a concentration-dependent manner, an effect abolished by SR-59230.

Conclusions

Inhibitory action of GW427353 involves release of SST which stimulates inhibitory SST2 receptors on human submucous neurons. Adipocytes are a potential source for SST. β3-AR activation may be a promising approach to reduce enteric neuron hyperexcitability. The action of GW427353 may be the neurophysiologic correlate of its beneficial effect in patients with irritable bowel syndrome.

Abbreviations used in this paper: ΔF/F, relative changes in fluorescence, AR, adrenoceptor, Di-8-ANEPPS, 1-(3-sulfonatopropyl)-4-β2-(di-n-octylamino)-6-naphthyl[vinyl]pyridinium betaine, ENS, enteric nervous system, EPSP, excitatory postsynaptic potential, IBS, irritable bowel syndrome, SST, somatostatin, SST2, somatostatin type 2, TH, tyrosine hydroxylase

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Conflicts of interest K.L. is an employee of GlaxoSmithKline, UK. S.C. and O.I.K. were employees of GSK at the time of the experiments. The remaining authors have no conflicts to disclose.

 Funding This study has been in part supported by a research grant from GlaxoSmithKline.

PII: S0016-5085(09)01696-5

doi:10.1053/j.gastro.2009.09.046

Gastroenterology
Volume 138, Issue 1 , Pages 266-274, January 2010